NCT02866006View on ClinicalTrials.gov

Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

December 31, 2021

Study Completion Date

June 30, 2022

Conditions
Uterine Cervical Neoplasms
Interventions
DRUG

BVAC-C

Autologous B cells and monocytes transfected with E6E7 gene of HPV

DRUG

Topotecan

Trial Locations (1)

Unknown

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Cellid Co., Ltd.

INDUSTRY

NCT02866006 - Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer | Biotech Hunter | Biotech Hunter